Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer.

Journal of gastrointestinal cancer - 1 Mar 2024

Santos Florinda A, Reis Rui Manuel, Barroti Lucas C, Pereira Allan A L, Matsushita Marcus M, de Carvalho Ana Carolina, Datorre José Guilherme, Berardinelli Gustavo N, Araujo Raphael L C

Abstract excerpt

PURPOSE: Evaluate overall survival (OS), RAS, BRAF, and MSI frequencies in patients with metastatic colorectal cancer (mCRC), refractory to chemotherapy, and finally treated with cetuximab. METHODS: A retrospective cohort study to evaluate 211 mCRC patients with wild-type KRAS treated with cetuximab. BRAF V600E, KRAS, NRAS gene mutations, and MSI status were identified using PCR techniques in a population of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Drug Resistance, Neoplasm

Share to GTP Phosphohydrolases

Share to Microsatellite Instability

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 37608030
DOI: 10.1007/s12029-023-00964-x

Genes

BRAF
NRAS
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer.PMID 37608030Read ↗

Conditional Overall Survival After Diagnosis of Non-Metastatic Colon Cancer: Impact of Laterality, MSI, and KRAS Status.Semantic proximity Read ↗

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.Semantic proximity Read ↗

Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.Semantic proximity Read ↗

BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics.Semantic proximity Read ↗

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?Semantic proximity Read ↗

Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.Semantic proximity Read ↗

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.Semantic proximity Read ↗

Surgical Resection for Local and Lateral Lymph Node Recurrence of MSI-high Cecal Cancer with the BRAF V600E Mutation.Semantic proximity Read ↗

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.Semantic proximity Read ↗

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.Semantic proximity Read ↗

p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.